Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Activation of The Metabolic Master Regulator PPARγ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Hansmann G, Calvier L, Risbano MG, Chan SY.

Am J Respir Cell Mol Biol. 2019 Oct 2. doi: 10.1165/rcmb.2019-0226PS. [Epub ahead of print]

PMID:
31577451
2.

Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension.

Sallmon H, Moledina S, Albert DC, Beghetti M, Berger RMF, Bonnet D, Bukova M, Koestenberger M, Meinel K, Reinhardt Z, Tulloh RMR, de Wolf D, Hansmann G.

Cardiol Young. 2019 Sep 26:1-5. doi: 10.1017/S104795111900235X. [Epub ahead of print]

PMID:
31554525
3.

2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT.

Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D'Alto M, Gatzoulis MA, Hasan BS, Kozlik-Feldmann R, Kumar RK, Lammers AE, Latus H, Michel-Behnke I, Miera O, Morrell NW, Pieles G, Quandt D, Sallmon H, Schranz D, Tran-Lundmark K, Tulloh RMR, Warnecke G, Wåhlander H, Weber SC, Zartner P.

J Heart Lung Transplant. 2019 Sep;38(9):879-901. doi: 10.1016/j.healun.2019.06.022. Epub 2019 Jun 21.

PMID:
31495407
4.

Emphysema is - at the most - only a Mild Phenotype in the Sugen-Hypoxia Rat Model of Pulmonary Arterial Hypertension.

Bogaard HJ, Legchenko E, Chaudhary KR, Sun X, Stewart DJ, Hansmann G.

Am J Respir Crit Care Med. 2019 Aug 22. doi: 10.1164/rccm.201906-1200LE. [Epub ahead of print] No abstract available.

PMID:
31437404
5.

Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle.

Chouvarine P, Legchenko E, Geldner J, Riehle C, Hansmann G.

J Mol Med (Berl). 2019 Oct;97(10):1427-1438. doi: 10.1007/s00109-019-01817-6. Epub 2019 Jul 23.

PMID:
31338525
6.

The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3.

Németh Á, Mózes MM, Calvier L, Hansmann G, Kökény G.

BMC Nephrol. 2019 Jul 5;20(1):245. doi: 10.1186/s12882-019-1431-x.

7.

Chronic TGF-β1 Signaling in Pulmonary Arterial Hypertension Induces Sustained Canonical Smad3 Pathways in Vascular Smooth Muscle Cells.

Calvier L, Chouvarine P, Legchenko E, Kokeny G, Mozes MM, Hansmann G.

Am J Respir Cell Mol Biol. 2019 Jul;61(1):121-123. doi: 10.1165/rcmb.2018-0275LE. No abstract available.

PMID:
31259625
8.

Ventricular-ventricular interaction variables correlate with surrogate variables of clinical outcome in children with pulmonary hypertension.

Koestenberger M, Sallmon H, Avian A, Cantinotti M, Gamillscheg A, Kurath-Koller S, Schweintzger S, Hansmann G.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019854074. doi: 10.1177/2045894019854074.

9.

Inhibition of neogenin fosters resolution of inflammation and tissue regeneration.

Schlegel M, Körner A, Kaussen T, Knausberg U, Gerber C, Hansmann G, Jónasdóttir HS, Giera M, Mirakaj V.

J Clin Invest. 2019 May 1;129(5):2165. doi: 10.1172/JCI128681. Epub 2019 May 1. No abstract available.

10.

LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.

Calvier L, Boucher P, Herz J, Hansmann G.

Circ Res. 2019 Jun 7;124(12):1778-1785. doi: 10.1161/CIRCRESAHA.119.315088. Epub 2019 Apr 26.

PMID:
31023188
11.

Sympathetic nervous system controls resolution of inflammation via regulation of repulsive guidance molecule A.

Körner A, Schlegel M, Kaussen T, Gudernatsch V, Hansmann G, Schumacher T, Giera M, Mirakaj V.

Nat Commun. 2019 Feb 7;10(1):633. doi: 10.1038/s41467-019-08328-5.

12.

A pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension.

Koestenberger M, Sallmon H, Hansmann G; European Pediatric Pulmonary Vascular Disease Network.

Int J Cardiol. 2019 Mar 1;278:242. doi: 10.1016/j.ijcard.2018.11.092. No abstract available.

PMID:
30683328
13.

Tricuspid annular plane systolic excursion (TAPSE) in pediatric pulmonary hypertension: Integrating right ventricular ejection efficiency (RVEe) into advanced multi-parametric imaging.

Koestenberger M, Avian A, Cantinotti M, Hansmann G; European Pediatric Pulmonary Vascular Disease Network.

Int J Cardiol. 2019 Jan 1;274:296-298. doi: 10.1016/j.ijcard.2018.07.013. Epub 2018 Jul 3.

PMID:
30454722
14.

Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018.

Olschewski A, Berghausen EM, Eichstaedt CA, Fleischmann BK, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs JK, Jonigk D, Kuebler WM, Kwapiszewska G, Pullamsetti SS, Stacher E, Weissmann N, Wenzel D, Schermuly RT.

Int J Cardiol. 2018 Dec 1;272S:4-10. doi: 10.1016/j.ijcard.2018.09.070. Epub 2018 Sep 20. Review.

PMID:
30314839
15.

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Koestenberger M, Hansmann G.

Pulm Circ. 2018 Jul-Sep;8(3):2045894018793580. doi: 10.1177/2045894018793580.

16.

Inhibition of neogenin fosters resolution of inflammation and tissue regeneration.

Schlegel M, Körner A, Kaussen T, Knausberg U, Gerber C, Hansmann G, Jónasdóttir HS, Giera M, Mirakaj V.

J Clin Invest. 2018 Oct 1;128(10):4711-4726. doi: 10.1172/JCI96259. Epub 2018 Sep 17. Erratum in: J Clin Invest. 2019 May 1;129(5):2165.

17.

Recommendations from the Association for European Paediatric and Congenital Cardiology for clinical training in paediatric heart failure and transplantation.

Reinhardt Z, Hansmann G, O'Sullivan J, Murtuza B, Köstenberger M, Schranz D, Bonnet D, Burch M.

Cardiol Young. 2018 Nov;28(11):1295-1298. doi: 10.1017/S1047951118001221. Epub 2018 Sep 12. Review.

PMID:
30207263
18.

Echocardiographic estimation of elevated right ventricular afterload in preterm infants at risk for pulmonary hypertension: next steps.

Koestenberger M, Hansmann G.

J Pediatr. 2018 Nov;202:335-336. doi: 10.1016/j.jpeds.2018.07.054. Epub 2018 Aug 23. No abstract available.

PMID:
30146114
19.

Reply to "Diagnostic and prognostic value of echocardiography in pulmonary arterial hypertension".

Koestenberger M, Avian A, Meinel K, Sallmon H, Hansmann G; European Pediatric Pulmonary Vascular Disease Network.

Clin Cardiol. 2018 Sep;41(9):1152-1153. doi: 10.1002/clc.23038. Epub 2018 Aug 21. No abstract available.

20.

Right ventricular base/apex ratio in the assessment of pediatric pulmonary arterial hypertension: Results from the European Pediatric Pulmonary Vascular Disease Network.

Koestenberger M, Avian A, Gamillscheg A, Sallmon H, Grangl G, Burmas A, Schweintzger S, Kurath-Koller S, Cvirn G, Hansmann G.

Clin Cardiol. 2018 Sep;41(9):1144-1149. doi: 10.1002/clc.22994. Epub 2018 Aug 18.

21.

Different indications for transcatheter and surgical patent ductus arteriosus closure in preterm infants less than 2kg.

Sallmon H, Berger F, Koehne P, Koestenberger M, Hansmann G, Opgen-Rhein B.

Int J Cardiol. 2018 Sep 1;266:83. doi: 10.1016/j.ijcard.2017.11.029. No abstract available.

PMID:
29887478
22.

PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.

Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M, Maegel L, Mitsialis SA, Rog-Zielinska EA, Kourembanas S, Jonigk D, Hansmann G.

Sci Transl Med. 2018 Apr 25;10(438). pii: eaao0303. doi: 10.1126/scitranslmed.aao0303.

PMID:
29695452
23.

Association between Platelet Counts before and during Pharmacological Therapy for Patent Ductus Arteriosus and Treatment Failure in Preterm Infants.

Sallmon H, Weber SC, Dirks J, Schiffer T, Klippstein T, Stein A, Felderhoff-Müser U, Metze B, Hansmann G, Bührer C, Cremer M, Koehne P.

Front Pediatr. 2018 Mar 7;6:41. doi: 10.3389/fped.2018.00041. eCollection 2018.

24.

The right ventricular outflow tract in pediatric pulmonary hypertension-Data from the European Pediatric Pulmonary Vascular Disease Network.

Koestenberger M, Avian A, Sallmon H, Gamillscheg A, Grangl G, Kurath-Koller S, Schweintzger S, Burmas A, Hansmann G.

Echocardiography. 2018 Jun;35(6):841-848. doi: 10.1111/echo.13852. Epub 2018 Mar 5.

PMID:
29505663
25.

First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.

Spreemann T, Bertram H, Happel CM, Kozlik-Feldmann R, Hansmann G.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217743123. doi: 10.1177/2045893217743123. Epub 2017 Nov 3.

26.

Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.

Koestenberger M, Hansmann G.

Pediatr Cardiol. 2017 Oct;38(7):1523-1524. doi: 10.1007/s00246-017-1699-1. Epub 2017 Aug 7. No abstract available.

PMID:
28785777
27.

Transforming Growth Factor β1- and Bone Morphogenetic Protein 2/PPARγ-regulated MicroRNAs in Pulmonary Arterial Hypertension.

Calvier L, Chouvarine P, Legchenko E, Hansmann G.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1227-1228. doi: 10.1164/rccm.201705-0923LE. No abstract available.

PMID:
28653861
28.

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension.

Geerdink LM, Bertram H, Hansmann G.

Pulm Circ. 2017 Apr-Jun;7(2):551-554. doi: 10.1177/2045893217703369. Epub 2017 May 12.

29.

Pulmonary Hypertension in Infants, Children, and Young Adults.

Hansmann G.

J Am Coll Cardiol. 2017 May 23;69(20):2551-2569. doi: 10.1016/j.jacc.2017.03.575. Review.

30.

PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism.

Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P, Jonigk D, Mozes MM, Hansmann G.

Cell Metab. 2017 May 2;25(5):1118-1134.e7. doi: 10.1016/j.cmet.2017.03.011.

31.

Circulating Endothelial Cell Quantification by Microfluidics Chip in Pulmonary Arterial Hypertension.

Sallmon H, Hatch A, Murthy SK, Plouffe BD, Hansmann G.

Am J Respir Cell Mol Biol. 2017 May;56(5):680-682. doi: 10.1165/rcmb.2017-0026LE. No abstract available.

32.

Normal Reference Values and z Scores of the Pulmonary Artery Acceleration Time in Children and Its Importance for the Assessment of Pulmonary Hypertension.

Koestenberger M, Grangl G, Avian A, Gamillscheg A, Grillitsch M, Cvirn G, Burmas A, Hansmann G.

Circ Cardiovasc Imaging. 2017 Jan;10(1). pii: e005336. doi: 10.1161/CIRCIMAGING.116.005336.

PMID:
28003222
33.

Diagnostics in Children and Adolescents with Suspected or Confirmed Pulmonary Hypertension.

Koestenberger M, Hansmann G, Apitz C, Latus H, Lammers A.

Paediatr Respir Rev. 2017 Jun;23:3-15. doi: 10.1016/j.prrv.2016.10.006. Epub 2016 Oct 26. Review.

PMID:
27964948
34.

[Pathobiology, pathology and genetics of pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016].

Olschewski A, Berghausen EM, Eichstaedt CA, Fleischmann BK, Grünig E, Grünig G, Hansmann G, Harbaum L, Hennigs JK, Jonigk D, Kübler WM, Kwapiszewska G, Pullamsetti SS, Stacher E, Weissmann N, Wenzel D, Schermuly RT.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S4-S9. Epub 2016 Oct 19. German.

PMID:
27760444
35.

Left Ventricular Diastolic Dysfunction in Pediatric Pulmonary Hypertension.

Hansmann G.

Circ Cardiovasc Imaging. 2016 Sep;9(9). pii: e005527. doi: 10.1161/CIRCIMAGING.116.005527. No abstract available.

PMID:
27581954
36.

Transthoracic echocardiography in the evaluation of pediatric pulmonary hypertension and ventricular dysfunction.

Koestenberger M, Friedberg MK, Nestaas E, Michel-Behnke I, Hansmann G.

Pulm Circ. 2016 Mar;6(1):15-29. doi: 10.1086/685051. Review.

37.

Right ventricular outflow tract velocity time integral (RVOT VTI) and tricuspid regurgitation velocity/RVOT VTI ratio in pediatric pulmonary hypertension.

Koestenberger M, Avian A, Grangl G, Burmas A, Kurath-Koller S, Hansmann G.

Int J Cardiol. 2016 Jun 1;212:274-6. doi: 10.1016/j.ijcard.2016.03.111. Epub 2016 Mar 24. No abstract available.

PMID:
27057933
38.

Executive summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.

Hansmann G, Apitz C, Abdul-Khaliq H, Alastalo TP, Beerbaum P, Bonnet D, Dubowy KO, Gorenflo M, Hager A, Hilgendorff A, Kaestner M, Koestenberger M, Koskenvuo JW, Kozlik-Feldmann R, Kuehne T, Lammers AE, Latus H, Michel-Behnke I, Miera O, Moledina S, Muthurangu V, Pattathu J, Schranz D, Warnecke G, Zartner P.

Heart. 2016 May;102 Suppl 2:ii86-100. doi: 10.1136/heartjnl-2015-309132.

PMID:
27053701
41.
43.
48.

The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension.

Hansmann G, Apitz C.

J Am Coll Cardiol. 2016 Mar 1;67(8):1009-10. doi: 10.1016/j.jacc.2015.10.102. No abstract available.

49.

Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus.

Sallmon H, Koehne P, Hansmann G.

Clin Perinatol. 2016 Mar;43(1):113-29. doi: 10.1016/j.clp.2015.11.008. Review.

PMID:
26876125
50.

Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.

Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK, Hansmann G.

Heart. 2016 Mar;102(5):390-6. doi: 10.1136/heartjnl-2015-308365.

PMID:
26869635

Supplemental Content

Loading ...
Support Center